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 Boron neutron capture therapy (BNCT) is an effective radiotherapy 
modality to kill cancer. BNCT can selectively kill cancer cells without 
damaging the healthy tissue around it by using alpha particle and lithium 
ion from the reaction of 10B(n,α)7Li. These particles have a track of more 
or less 5 to 9 μm which is the same as the cell diameter. In order to support 
the development of BNCT in Indonesia an in vivo simulation is performed 
in a simple mouse geometry containing a 4T1 breast cancer characteristic 
treated with BNCT using PHITS program. The Neutron source that was 
used in this simulation was based on TRIGA Kartini Research Reactor. 
The boron compound concentration in the tumor was varied from 20 ppm 
up to 90 ppm, and then the total dose was calculated in the mice. Total 
dose that the tumor received was 0.0161, 0.0168, 0.0175, 0.0182, 0.0185, 
0.0188, 0.019, and 0.0191 Gy-Eq/s, respectively and the irradiation time 
to reach 50 Gy was 51, 50, 48, 46, 45, 45, 44, 44, 40 minutes respectively. 
This shows that the higher the concentration of boron compound in the 
tumor the higher the dose that mice received and irradiation time was 
decreased with the increase of the boron compound concentration. 
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1. INTRODUCTION 
Boron Neutron Capture Therapy (BNCT) is 
one of the treatments that is developed 
throughout the world today including in 
Indonesia. There are many stages in the 
development of BNCT; one of which is trial on 
small animals (in vivo). Studies in small animals 
perform as an approach to human tests for a 
treatment. BNCT was applied in rats with 
colorectal liver metastasis using BPA as boron 
compound, this shows that after a 5-week 
follow-up there is no liver toxicity detected in 
the rats (Emilliano et al 2013). Another BNCT 
study was perform in a hamster with head and 
neck cancer, after a 16-week follow-up time no 
radiotoxicity was observed (Elisa M. Hebera 
2014). 
                                                    
 E-mail: ramadhan7valiant@gmail.com 
BNCT has a promising result in cancer 
treatment because it can selectively kill cancer 
cells without giving great damage to the healthy 
tissue around cancer by use of the alpha particle 
and ion lithium from the reaction of boron and 
thermal neutron 10B(n,α)7Li in the body and it 
is estimated that the particle track of the alpha 
and ion lithium is the same as cell diameter up 
to 9 μm (Shinji Kawabata, M.D., et al 2013). 
Doses in the BNCT are very different and more 
complex from doses in other radiotherapy. 
BNCT has four components of doses which are 
doses from photon absorbed dose, fast neutron 
absorbed dose, nitrogen absorbed dose, and 
boron absorbed dose (Carl Ostlund 2005). There 
are 2 types of common boron compound that are 
used in BNCT which is BSH and BPA. 
Optimizing BNCT treatment can be done by 
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improving the delivery of the boron carrier to 
the tumor (V. A. Trivillin., et al 2013). 
Selectivity of BNCT to cancer treatment is 
affected by ration of boron concentration in 
tumor and healthy tissue (Yoshiaki Yura, 2012). 
In order to support a planning for 
experiments on BNCT, simulation was 
performed. Dosimetric efficacy of BNCT in 
liver metastases and liver cancer are 
investigated by simulation using MCNP and it 
shows that simulation using MCNP has  
potential (M. Blaickner, 2011). Another 
program used to simulate BNCT is PHITS, 
which can simulate a full-body phantom doses 
resulting from irradiation in BNCT treatment 
(Kenta Takada 2014) and also simulate an 
absorbed dose and neutron energy spectra 
resulting from accelerator (Monika Puchalska 
2015). 
In this study we simulated in vivo trial use 
PHITS program developed by Japan Atomic 
Energy Agency and calculated the total dose of 
each boron concentration that varies from 20 
ppm up to 90 ppm. We used simple ellipsoid 
geometry as a mice body and a simple spherical 
geometry in the mice body as a tumor. The goal 
of this study is to support, provide data and 
reference for an experiment in the in vivo test in 
TRIGA Kartini Reactor. The Boron compound 
that was used in this study is BSH. 
2. MATERIALS AND METHODS 
2.1 Neutron Source and in vivo test facility 
design 
This simulation used a neutron source based 
on characteristic thermal column TRIGA 
Kartini Research Reactor in Indonesia. We used 
a collimator design based on the previous study 
in simulation using MCNP to design a 
collimator for BNCT trial in thermal column 
TRIGA Kartini Reactor (M.Ilma Muslih 
Arrozaqi 2014). Neutron flux that came out 
from the aperture of the collimator in the 
simulation is 5.56 × 108. This result is still 
proper for BNCT trial. Small animals were put 
in a box as an in vivo facility with a volume 30 
× 30 × 30 cm3 that was made from Al (Figure.1). 
 
Fig. 1 Neutron source design which consists of collimator, moderator, filter, and in vivo facility based on TRIGA 
Kartini Research Reactor. Collimator design consists of 95% of nickel, Al as a filter, Pb, and Boral. In front of 
collimator there is a box made from Al with a volume 30 × 30 × 30 cm3 filled with a mice.
2.2 Animal Model 
We created simple ellipsoid geometry as a 
mice body consists with cancer in a form of a 
small spherical geometry inside the ellipsoid. 
We use 4T1 breast cancer in this study, in 5th 
week the tumor growth has reached a volume of 
1000 mm3 (Bailey-Downs LC 2014). 
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Component of the breast cancer is set up 
according to ICRU 44 (ICRU 1989). Figure 2 
shows the geometry of the animal model. 
 
Fig. 2 Mice model with a 2 cm diameter 4T1 tumor in a 
box made from Al. 
2.3 Evaluating Total Dose in Mice 
Simulation using PHITS program (Particle 
and Heavy Ion Transport Code System) 
developed by Japan Atomic Energy Agency, we 
use two calculation mode; first based on tally 
[T-Deposit] in PHITS program, and second 
using kerma factor conversion as a multiplier in 
PHITS from flux to dose. The physical absorbed 
doses from the simulation convert to photon 
equivalent doses by multiplying each 
component of doses with the weighted factor 
(Minoru Suzuki 2014). In this simulation we 
vary the boron concentration in tumor which is 
20 ppm, 30 ppm, 40 ppm, 50 ppm, 60 ppm, 70 
ppm, 80 ppm, and 90 ppm. Volume of the tumor 
is the same for every boron concentration that is 
1 mm3, and also mice and irradiation position is 
the same. 
3. RESULTS AND DISCUSSION 
Neutron flux distribution that came out in 
the aperture of the collimator by using PHITS 
program is 5. 941 × 108 Figure.3 this result is not 
very far from the previous study where neutron 
flux that came out in the aperture using MCNP 
simulation was 5.56 × 108 (Ilma Muslih 
Arrozaqi 2014). This result of neutron flux is 
still proper to use in the BNCT trial. In the 
previous study reactor criticality simulation 
with MCNP performed in order to get neutron 
output from the TRIGA Kartini reactor core, but 
in this PHITS simulation reactor criticality is not 
performed. We take the neutron spectrum output 
from the reactor core in MCNP simulation and 
use it as source input in our PHITS simulation.
 
Fig. 3 Neutron flux distribution in the collimator, in vivo facility, and in the mice. Neutron flux that out from collimator 
is 5.55 × 108 and in the mice neutron flux is 1.2 × 107.
Table. 1 shows distribution of BNCT four 
component physical absorbed doses in mice. 
With the change of the boron concentration in 
the tumor boron absorbed doses increased, 
while the proton absorbed dose decreased. The 
neutron absorbed dose and the photon absorbed 
dose also change but only in a small fraction. 
Increasing of boron absorbed dose with the 
increasing of the boron concentration is due to 
the boron concentration in the tumor that 
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increased.  With this increased concentration the 
producing of alpha particle and lithium ion in 
the tumor becomes higher. 
Table. 2 shows the total weighted dose that 
has been multiplied with the weighting factor of 
each component dose (Wolfgang 2012) in mice 
tumor. It also shows the irradiation time needed 
to reach dose 50 Gy-eq. With the increasing 
boron concentration in tumor the irradiation 
time becomes shorter. This is because high 
boron concentration produces more alpha and 
lithium ion. This result of irradiation times for 
in vivo simulation if compared to the previous 
study that using MCNP to simulate in vivo trial 
of BNCT (Adrian T. 2016) is more or less two 
times shorter. This is because in this simulation 
we did not define the GTV, CTV, and PTV and 
the mice geometry simpler than before.
Table. 1 Four component doses and total doses of bnct in mice. 
Boron concentration in 
tumor (ppm) 
Dose (Gy/s) 
Boron 14N(n, p)14C Neutron Photon Total 
20 6.09E-03 1.01E-04 1.60E-04 1.34E-04 6.49E-03 
30 6.36E-03 9.89E-05 1.60E-04 1.34E-04 6.75E-03 
40 6.64E-03 9.74E-05 1.59E-04 1.34E-04 7.03E-03 
50 6.91E-03 9.01E-05 1.59E-04 1.34E-04 7.30E-03 
60 7.07E-03 8.49E-05 1.59E-04 1.34E-04 7.44E-03 
70 7.18E-03 7.67E-05 1.59E-04 1.34E-04 7.55E-03 
80 7.25E-03 8.02E-05 1.59E-04 1.34E-04 7.62E-03 
90 7.29E-03 7.39E-05 1.59E-04 1.34E-04 7.66E-03 
 
Table. 2 Total weighted doses of each boron concentration and irradiation time. 
Boron concentration in 
tumor (ppm) 
Total dose weighted 
(Gy-eq/s) 
Irradiation Time to 
reach 50 Gy (s) 
Irradiation time to reach 
50 Gy (minutes) 
20 1.61E-02 3.10E+03 5.16E+01 
30 1.68E-02 2.98E+03 4.96E+01 
40 1.75E-02 2.86E+03 4.76E+01 
50 1.82E-02 2.75E+03 4.59E+01 
60 1.85E-02 2.70E+03 4.50E+01 
70 1.88E-02 2.66E+03 4.44E+01 
80 1.90E-02 2.64E+03 4.39E+01 
90 1.91E-02 2.62E+03 4.37E+01 
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4. CONCLUSION AND REMARKS 
We have studied the simulation of BNCT in 
vivo trial based on the TRIGA Kartini Research 
Reactor using PHITS. We evaluated the total 
dose and the irradiation time needed to reach 50 
Gy-eq while we vary the boron concentration in 
mice tumor. We found that with the increasing 
of boron concentration in mice the total dose 
also increases and the irradiation time becomes 
shorter. 
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